Drug intelligence / Profile preview

SPARC1310

Development stage: Phase 2
Lead developer: SPARC
Modality: Small Molecules

Overview

SPARC1310 is a small molecule drug candidate developed for the treatment of seasonal allergic rhinitis. It has been evaluated in clinical trials for its efficacy and safety compared to placebo and active control. The precise mechanism of action has not been disclosed or remains uncharacterized, with available sources indicating "no mechanism" or "novel mechanism: no." The drug was developed by Sun Pharma Advanced Research Company Limited (SPARC), a subsidiary of Sun Pharmaceutical Industries, focusing on innovative therapies and novel formulations[1][2].

Other names: SPARC-1310SPARC1310SPARC 1310

Beyond the preview

Go deeper on SPARC1310.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPARC1310.

Explore the full profile